Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (September 4th Preview)
-
Cardiometabolic / GLP-1 partnerships and regional expansion
Menarini struck a large European licensing deal for Gan & Lee’s biweekly GLP-1 obesity candidate, bofanglutide, extending the drug into 39 European countries. The agreement is structured around an upfront €62 million payment, milestone funding that can reach €664 million, and double-digit royalties. The move underscores how quickly European obesity players are repositioning around next-generation incretin formats. It also highlights Gan & Lee’s strategy to retain commercial rights in markets outside Europe while monetizing development and launch economics via regional partners.
-
Regulatory approval – first-in-class for ultra-rare Alexander disease
The FDA approved Ionis Pharmaceuticals’ antisense therapy Zanvastro (zilganersen) for pediatric and adult patients with Alexander disease, establishing the first disease-modifying treatment for the ultra-rare neurological disorder. Ionis said Zanvastro is expected to be available in the coming weeks. The pivotal program reported stabilization signals using clinical measures of motor function, including walking speed, with serious adverse events appearing less frequent in the Zanvastro arm versus control in the reported results. The agency granted a rare pediatric disease priority review voucher to accelerate review.
-
Cardiovascular late-stage failure – pelacarsen
Novartis disclosed that pelacarsen failed to meet endpoints in a pivotal Phase 3 outcome trial, a major setback for the company’s Lp(a)-lowering strategy in preventing cardiovascular events. In the HORIZON study, the antisense therapy did not reduce cardiovascular death or emergencies such as heart attacks or stroke versus placebo. The failure sharpens scrutiny on whether Lp(a) reduction translates into hard clinical outcomes, despite earlier trials showing large reductions in Lp(a) biomarkers. Novartis will now reassess its cardiovascular pipeline priorities and future study designs.
-
Oncology – Phase 3 readouts reshape treatment risk-benefit
AbbVie reported a Phase 3 win for its T-cell engager etentamig in multiple myeloma, meeting the trial’s main goal. Company results indicated a 60% risk reduction for disease progression or death compared with standard regimens, with safety data emphasizing low rates of serious immune-related adverse events relative to comparator therapies. The program enrolled 421 patients and moved through an interim checkpoint that triggered unblinding after independent trial monitors detected differences. AbbVie framed the profile as potentially enabling broader use in community oncology by reducing post-treatment monitoring intensity.
-
Oncology partnering – GSK licenses KRAS–EGFR antibody-targeted conjugate from Hutchmed
GSK agreed to license Hutchmed’s HMPL-A830, a KRAS–EGFR antibody-targeted therapy conjugate, in a deal valued at up to $1.295 billion. GSK will pay $110 million upfront for rights to develop and commercialize outside mainland China, Hong Kong, Macau, and Taiwan, while Hutchmed keeps those regional rights. The asset links an anti-EGFR antibody with a KRAS small-molecule inhibitor payload and is designed to concentrate the payload in tumors expressing EGFR while blocking EGFR and KRAS signaling. GSK plans initial clinical development across colorectal, pancreatic, and lung cancer, with a Phase 1 start expected in the second half of 2026.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.